Eli Lilly's Retatrutide Achieves Significant Weight Loss in Phase 3 Obesity Trial
Eli Lilly's experimental drug retatrutide demonstrated substantial weight loss in a Phase 3 trial, with participants losing up to 28.3% of their body weight over 80 weeks.
Eli Lilly's investigational drug, retatrutide, has shown significant weight loss results in a Phase 3 clinical trial involving patients with obesity. Participants receiving the highest dose experienced an average weight reduction of 28.3% over 80 weeks, compared to a 2.2% loss in the placebo group. Approximately 45% of the 2,500 participants achieved a weight loss of 30% or more.
Retatrutide is a once-weekly injection that targets three gut hormones: GLP-1, GIP, and glucagon. This mechanism appears to enhance appetite suppression and satisfaction more effectively than existing treatments.
The trial also reported higher rates of gastrointestinal side effects, such as nausea and diarrhea, particularly at the highest dose. However, these side effects were generally consistent with previous studies. A lower dose tested in the study was associated with fewer discontinuations due to side effects.
Dan Skovronsky, Lilly's chief scientific and product officer, noted that achieving 30% weight loss is an "incredible number to see," as it has previously only been associated with bariatric surgery.
These results position retatrutide as a potential new option in the competitive weight-loss drug market, pending further trials and regulatory approval.
